Medical Therapy for Asthma: Updates from the NAEPP Guidelines

Area of Science:

• Pulmonology
• Allergy and Immunology
• Pharmacology

Background:

• Asthma care requires a comprehensive approach including chronic care plans, self-management support, and appropriate medical therapy.
• Controller medications are essential for managing persistent asthma, aiming for long-term symptom control.

Purpose of the Study:

• To outline the foundational controller medications for persistent asthma.
• To discuss the efficacy and safety of inhaled corticosteroids, long-acting beta2 agonists, and leukotriene receptor antagonists.
• To provide guidance on initiating or intensifying anti-inflammatory therapy based on short-acting beta2 agonist use.

Main Methods:

• Review of established asthma management guidelines and pharmacological principles.
• Analysis of clinical evidence supporting the use of various controller medications.
• Evaluation of treatment strategies for different asthma severities and control levels.

Main Results:

• Inhaled corticosteroids (ICS) are the preferred first-line controller medication for persistent asthma.
• Combination therapy of ICS and long-acting beta2 agonists (LABA) is effective when ICS alone is insufficient.
• Leukotriene receptor antagonists (LTRA) serve as a second-line option for mild persistent asthma or adjunctive therapy.

Conclusions:

• Consistent daily use of controller medications, particularly ICS, is crucial for maintaining asthma control.
• Increased use of short-acting beta2 agonists indicates poor asthma control and the need for intensified anti-inflammatory treatment.
• Oral systemic corticosteroids are reserved for managing moderate to severe asthma exacerbations.